Opiant Pharmaceuticals, Inc. (NasdaqGM: OPNT)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Opiant Pharmaceuticals, Inc. (NasdaqGM: OPNT) operates in the Pharmaceuticals industry within the Health Care sector.
Tweenvest scores Opiant Pharmaceuticals, Inc. across four factors: quality 60/100, growth 100/100. Its strongest factor is growth.
OPNT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $22.34M
- P/E
- —
- EPS
- -6.62
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 37
- Next earnings
- —
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.
- ISIN
- US6837501039
- Founded
- 2005
- Listed since
- Jun 4, 2007
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,239.32 | -0.61% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.18 | +0.05% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.08 | +3.60% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.37 | +1.41% |
Figures last refreshed Aug 18, 2026.